Pilgrim

Based in the US, Pilgrim designs and produces advanced biotechnology solutions aimed at enhancing military capabilities and resilience, addressing vulnerabilities posed by emerging threats and environmental challenges. Pilgrim specializes in developing biotechnology solutions for military applications. Founded in 2023 in Redwood City, US, the company has secured funding through a SEED round led by Cantos Ventures, raising USD 4. 3 mn.

The company has engaged in one deal to date with its most recent funding round occurring on August 2, 2025. Pilgrim focuses on providing tailored solutions for military organizations and has no known subsidiaries or parent companies. Specific details about the founder are not available, but the company operates under a strategic model for long-term partnerships with defense contractors. Pilgrim specializes in developing and deploying advanced biotechnology solutions specifically designed for military applications.

Their core offerings focus on enhancing the capabilities and resilience of warfighters by addressing vulnerabilities associated with emerging threats and environmental challenges. The technologies aim to improve operational effectiveness through innovative applications of biological science, thereby transforming theoretical concepts into practical, battlefield-ready solutions. Pilgrim's client base primarily consists of military organizations and defense contractors, with a strategic focus on markets within North America and Europe. Their products are tailored to meet the needs of frontline personnel, ensuring that they are equipped to handle the rigors of modern warfare, thus reinforcing the human element in conflict resolution.

Pilgrim's revenue model is structured around B2B transactions, primarily involving partnerships with military and defense organizations. The company engages in direct sales of its biotechnology solutions, focusing on long-term contracts and agreements that ensure continued collaboration and support for its clients. Specific pricing plans and transaction structures are designed to reflect the unique needs of military applications, often involving customized solutions that align with the operational requirements of each client. Through these strategic partnerships, Pilgrim not only provides its flagship products but also offers ongoing services to enhance and adapt its technologies as the operational landscape evolves.

In August 2025, Pilgrim raised USD 4. 3 mn in Seed funding led by Cantos Ventures, with participation from Thiel Capital Management, Day One Ventures, and Refactor Capital. The company intends to utilize this funding to advance the development of battlefield-ready medical devices, including its hemostatic dressing Kingsfoil, and to secure regulatory approval. Pilgrim is also exploring expansion into new markets, specifically targeting additional defense sectors in North America and Europe by the end of 2026.